FDA Approval Alert: The Need-to-Know | Pacritinib for Myelofibrosis With Severe Thrombocytopenia

In February 2022, the FDA granted accelerated approval to pacritinib for intermediate or high-risk primary or secondary myelofibrosis with severe thrombocytopenia.

Mesa Considers Next Steps With Pacritinib in Myelofibrosis
Mesa Considers Next Steps With Pacritinib in Myelofibrosis
Video
Mar 4, 2022 9:00 PM
Ruben Mesa, MD, spoke about why pacritinib in the treatment of myelofibrosis is beneficial.
Mesa Talks Benefits of Pacritinib in Myelofibrosis With Marked Thrombocytopenia
Mesa Talks Benefits of Pacritinib in Myelofibrosis With Marked Thrombocytopenia
Video
Mar 2, 2022 10:00 PM
Ruben Mesa, MD, spoke about which patients stand to benefit the most from the approval of pacritinib in myelofibrosis with severe thrombocytopenia.
Patients with myelofibrosis with severe thrombocytopenia and a platelet count below 50 × 109/L may derive benefit from treatment with pacritinib following its accelerated approval by the FDA.
Pacritinib Granted Accelerated Approval for Use in Myelofibrosis With Severe Thrombocytopenia
Article
Mar 1, 2022 3:41 AM
Patients with intermediate- or high-risk primary or secondary myelofibrosis with a low platelet count may derive benefit from treatment with pacritinib following its accelerated approval by the FDA.
Ruben Mesa, MD, spoke about the approval of pacritinib and its importance for the treatment of myelofibrosis.
Mesa Discusses Importance of Pacritinib Accelerated Approval for Myelofibrosis With Severe Thrombocytopenia
Video
Mar 1, 2022 3:34 AM
Ruben Mesa, MD, spoke about the accelerated approval of pacritinib and its importance for the treatment of myelofibrosis with severe thrombocytopenia.